FXCM Share Buyout on the Table? Charles Schwab Emerges as Possible Suitor
Charles Schwab Corp has emerged as a darkhorse candidate to buyout shares of FXCM (NYSE:FXCM), following the recent Leucadia lifeline
Charles Schwab Corp has emerged as a darkhorse candidate to buyout shares of FXCM (NYSE:FXCM), following the recent Leucadia lifeline last week, with a premium of $5.25 per share being seen as a plausible figure, according to a Benzinga report.
While on the surface the emergence of Charles Schwab as a takeover candidate would appear to be ‘out of left field’, the two firms have an existing relationship. As reported in May 2013, Charles Schwab is a white label customer of FXCM, having integrated their forex services within the OptionsXpress platform. Therefore, management from the two firms have familiarity with each other which would help Charles Schwab in its analysis of an FXCM buyout.
Join the iFX EXPO Asia and discover your gateway to the Asian Markets
Suggested articles
Turkish Lira Trades Near Record Lows on Unorthodox Monetary PoliciesGo to article >>
Speaking to Benzinga about the potential of Charles Schwab as a buyer, Jeff Wilkins, Managing Director of ThinkLiquidity, stated the rumor made sense “Last week, the stock was trading around $17, and the only thing different is the cash situation and possible reputational damage, if Charles Schwab is a suitor, it brings immediate credibility to the table.”
At the time of writing, FXCM’s share price was hovering at $2.41 per share (-22.26%) during US trading. A possible buyout by either Charles Schwab or any unnamed entity certainly has the potential to throw the price into an even greater state of volatility, following the recent suspension of trading and consequent -88% loss in share price earlier this week.
Earlier today, it was revealed that FXCM drew an investigation from Kirby McInerney LLP, exploring claims against the firm’s Board of Directors. This occurred on the heels of last week’s CFTC investigation, as well as two US law firms publicly stating that they are investigating FXCM for possible violations of the Securities Exchange Act 1934 10(b) and 20(a).
I do not see how someone will pay $5.25 premium per share. This would be a total bargain for current shareholders.
FXCM will sell in April for around $2 premium while market value per share will be around $1
So buy a bunch… You will be rich. Or better, short the stock.
I bet you trade on a non regulated broker with a 400:1 two nano lots of eurusd and talk like you were Buffet. You are funny
To say that not much has changed for FXCM shareholders is wrong. They are now way at the back of the line behind Leucadia, who get as much as 90% of any dividends or sale proceeds. Almost complete dilution.
The $5.25 price seems arbitrary, and the lack of a by-line on the Benziga report should call into question the credibility of the “news” about Schwab.